Intragastric balloon therapy belongs to the field of bariatric gastroenterology (digestive specialty focused on weight management). Its primary clinical goal is inducing weight loss in adults with obesity who have not achieved sufficient results through diet and exercise alone. By physically occupying space within the stomach lumen and delaying gastric emptying (the rate at which food leaves the stomach), the device helps patients adhere to reduced-calorie nutrition plans.

The patient is positioned in the left lateral decubitus position under conscious sedation or monitored anesthesia care. A diagnostic upper endoscopy is performed to inspect the esophagus, stomach, and duodenum for contraindications such as large hiatal hernia or active ulceration. The deflated balloon catheter is introduced orally into the stomach under endoscopic visualization. The balloon is inflated with sterile isotonic saline (often mixed with methylene blue dye as an indicator) or gas to a volume of 400 to 700 mL. The inflation catheter is detached, and the balloon is inspected to ensure self-sealing and correct position within the gastric fundus or body. The endoscope is withdrawn, and the patient is monitored in recovery until discharge criteria are met.

• Non-Surgical and Reversible: Requires no structural alterations to the gastrointestinal tract, preserving native anatomy.
• Clinically Significant Weight Loss: Demonstrates superior total body weight loss compared to lifestyle intervention alone in peer-reviewed trials.
• Metabolic Health Improvements: Induces clinically meaningful reductions in glycated hemoglobin (HbA1c), fasting insulin, and serum triglycerides.
• Outpatient Convenience: Performed as a day procedure with minimal clinical downtime and rapid return to routine activities.
• Bridge Option: Serves as an effective risk-reduction tool prior to elective orthopedic, abdominal, or cardiac surgical operations.

Immediate recovery involves managing transient accommodation symptoms, such as nausea, emesis, and epigastric discomfort, which typically peak within 48 to 72 hours. Anti-emetic and antispasmodic medications are routinely prescribed. Patients follow a strict liquid diet for the first week, advancing to soft foods in week two, and resuming solid foods by week three. Routine physical activity can usually be resumed within 3 to 5 days following placement.

Intragastric balloon therapy is indicated for treating Class I and Class II obesity (excessive body fat accumulation with a body mass index of 30 to 40 kg/m²). It is also utilized as a bridge therapy to reduce perioperative risk in individuals requiring non-bariatric surgical procedures or as a metabolic intervention to improve obesity-related comorbidities such as type 2 diabetes, systemic hypertension, and hepatic steatosis.

Pre-procedure preparation requires a thorough medical history, laboratory evaluation, and dietary assessment. Patients must follow a clear liquid diet for 24 to 48 hours and maintain complete fasting (NPO) for at least 8 to 12 hours prior to placement. Prophylactic oral or intravenous proton pump inhibitors (PPIs) are initiated 3 to 7 days before placement to suppress gastric acid production and minimize mucosal irritation. Antiemetic medications are administered peri-operatively.

Common and mild side effects include post-placement nausea, vomiting, abdominal cramping, and gastroesophageal reflux occurring in up to 80% of patients during the first week. Less common complications include persistent accommodation intolerance requiring early device extraction (2% to 5%), gastric mucosal ulceration, and balloon deflation. Rare but serious risks include hyperinflation, acute pancreatitis due to extrinsic pressure on the pancreatic duct, gastric perforation, and small bowel obstruction secondary to migration of a deflated balloon.

The clinical journey begins with a multi-disciplinary evaluation involving a gastroenterologist, dietitian, and bariatric specialist. During pre-treatment, patients undergo diagnostic testing and nutritional counseling. Placement is an outpatient procedure taking 20 to 30 minutes under mild sedation or without sedation for swallowable devices. Patients transition from a liquid to a solid diet over three weeks while receiving continuous metabolic and dietary follow-up. After 6 to 12 months, the balloon is safely explanted or self-empties and passes naturally, followed by ongoing weight maintenance support.